KNSA (Kiniksa Pharmaceuticals International) Total Operating Expense: $318.9 Mil (TTM As of Mar. 2026)


KNSA Kiniksa Pharmaceuticals International PLC KNSA
54 GF Score
Price $64.53
GF Value $48.19
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Total Operating Expense?

Kiniksa Pharmaceuticals International KNSA +2.62% 54 Total Operating Expense is $318.9 Mil as of Mar. 2026. GuruFocus rates KNSA with a GF Score™ of 54/100 and a GF Value™ of $48.19 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Kiniksa Pharmaceuticals International's Total Operating Expense for the three months ended in Mar. 2026 was $88.6 Mil. Kiniksa Pharmaceuticals International's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $318.9 Mil.

Kiniksa Pharmaceuticals International Total Operating Expense Related Terms

Kiniksa Pharmaceuticals International Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Kiniksa Pharmaceuticals International's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Total Operating Expense Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 185.25 163.44 205.52 279.63 293.13

Kiniksa Pharmaceuticals International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.86 65.62 73.27 91.38 88.63
KNSA
54GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiniksa Pharmaceuticals International Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $318.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $318.9 Mil mean?
Kiniksa Pharmaceuticals International (KNSA) has a Total Operating Expense of $318.9 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Kiniksa Pharmaceuticals International and its competitors.
Is Kiniksa Pharmaceuticals International's Total Operating Expense too high?
Kiniksa Pharmaceuticals International's current Total Operating Expense is $318.9 Mil. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Total Operating Expense compare to INDV and AMRX?
Kiniksa Pharmaceuticals International's Total Operating Expense of $318.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Kiniksa Pharmaceuticals International and its competitors. Kiniksa Pharmaceuticals International's current Total Operating Expense is $318.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.19, compared to a current price of $64.53 — trading 33.9% above its estimated fair value. The current Total Operating Expense is $318.9 Mil. Kiniksa Pharmaceuticals International's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Total Operating Expense is $318.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $64.53 is trading 33.9% above its estimated GF Value™ of $48.19. GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.

Key valuation signals for KNSA:

  • Total Operating Expense: $318.9 Mil
  • GF Value™: $48.19 vs. price of $64.53 (33.9% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
54GF Score

Get the complete analysis for KNSA

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$64.53
Price
$48.19
GF Value